Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia
Authors:
- Marina Ribas LosassoMLMarina Ribas Losasso
- Maria Luiza Cesto ParussoloMPMaria Luiza Cesto Parussolo
- Antony Oliveira SilvaAntony Oliveira Silva
- Rosa DireitoRosa Direito
- Karina QuesadaKQKarina Quesada
- Claudia Rucco Penteado DetregiachiCDClaudia Rucco Penteado Detregiachi
- Marcelo Dib BecharaMBMarcelo Dib Bechara
- Nahum Méndez-SánchezNahum Méndez-Sánchez
- Ludovico AbenavoliLudovico Abenavoli
- Adriano Cressoni AraújoAdriano Cressoni Araújo
- Ricardo de Alvares GoulartRGRicardo de Alvares Goulart
- Elen Landgraf GuigerElen Landgraf Guiger
Open Access
- 14 May 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (10) , 4673
Abstract
Metabolic-Associated Fatty Liver Disease (MAFLD) is a public health concern that is constantly expanding, with a fast-growing prevalence, and it affects about a quarter of the world’s population. This condition is a significant risk factor for cardiovascular, hepatic, and oncologic diseases, such as hypertension, hepatoma, and atherosclerosis. Sarcopenia was long considered to be an aging-related syndrome, but today, it is acknowledged to be secondarily related to chronic diseases such as metabolic syndrome, cardiovascular conditions, and liver diseases, among other comorbidities associated with insulin resistance and chronic inflammation, besides inactivity and poor nutrition. The physiopathology involving MAFLD and sarcopenia has still not been solved. Inflammation, oxidative stress, mitochondrial dysfunction, and insulin resistance seem to be some of the keys to this relationship since this hormone target is mainly the skeletal muscle. This review aimed to comprehensively discuss the main metabolic and physiological pathways involved in these conditions. MAFLD and sarcopenia are interconnected by a complex network of pathophysiological mechanisms, such as insulin resistance, skeletal muscle tissue production capacity, chronic inflammatory state, oxidative stress, and mitochondrial dysfunction, which are the main contributors to this relationship. In addition, in a clinical analysis, patients with sarcopenia and MAFLD manifest more severe hepatitis fibrosis when compared to patients with only MAFLD. These patients, with both disorders, also present clinical improvement in their MAFLD when treated for sarcopenia, reinforcing the association between them. Lifestyle changes accompanied by non-pharmacological interventions, such as dietary therapy and increased physical activity, undoubtedly improve this scenario.Keywords
This publication has 246 references indexed in Scilit:
- Sarcopenia and Sarcopenic Obesity and Mortality Among Older PeopleJAMA Network Open, 2024
- Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative reviewFood Science & Nutrition, 2024
- The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean populationJournal of Cachexia, Sarcopenia and Muscle, 2022
- Nonalcoholic Fatty Liver Disease and Accelerated Loss of Skeletal Muscle Mass: A Longitudinal Cohort StudyHepatology, 2022
- Pathogenesis of sarcopenia and the relationship with fat mass: descriptive reviewJournal of Cachexia, Sarcopenia and Muscle, 2022
- Predicted fat mass and lean mass in relation to all‐cause and cause‐specific mortalityJournal of Cachexia, Sarcopenia and Muscle, 2022
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide surveyJournal of Cachexia, Sarcopenia and Muscle, 2021
- Association of Sarcopenia and NAFLD: An OverviewClinical Liver Disease, 2020
- Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011)Hepatology, 2015